VNRX - VolitionRx Ltd.

Sponsored segment highlighting VolitionRx's nucleosome-based blood tests for sepsis, cancer, and veterinary use. The company has peer-reviewed data, a global diagnostics partner, and several catalysts over the next two quarters, but it is a small, speculative early-stage stock.

Sponsored segment for a small-cap epigenetics company developing blood tests for sepsis, cancer, and pet cancer. Peer-reviewed data, low-cost tests, and a licensing model with big diagnostics partners. Several dated catalysts over the next two quarters, including potential milestone payments and publication of studies, but the host acknowledges it is a very risky, early-stage small cap.

Sponsored segment. The host presents VolitionRx as a small diagnostics company with promising cancer and sepsis blood test technology, proven in veterinary applications and expanding to human diagnostics. He notes significant TAM ($4B cancer screening, $23B multi-cancer early detection, $3B+ sepsis, $170M veterinary) but also highlights substantial risks: not yet profitable, no FDA approval, dilution risk from convertible notes, and uncertain regulatory pathway. He encourages viewers to do their own due diligence.

Sponsored segment. The host presents the company's cancer and sepsis diagnostics technology, licensing model, and market opportunity ($4B cancer screening, $23B multi-cancer early detection, $3B+ sepsis, $170M veterinary). However, he explicitly acknowledges significant risks: not yet profitable, no FDA approval, dilution risk from convertible notes, and no guarantee of additional licensing deals. He tells viewers to do their own due diligence.

Sponsored segment presents VNRX as a diagnostics company worth putting on your radar. The company has proven technology in veterinary diagnostics (NU.Q Vet cancer test launched worldwide, 120,000+ tests sold) and is pursuing human diagnostics for cancer screening and sepsis. However, the presenter acknowledges significant risks: not yet profitable, no FDA approval, dilution risk from convertible notes, and early-stage licensing discussions. Presented more as an interesting watchlist candidate than a direct buy recommendation.

Sponsored segment. VNRX is a diagnostics company developing simple blood tests for cancer detection (NU.Q) and sepsis (NU.Q NETS). The veterinary cancer test is already launched worldwide with 120,000+ tests sold. Human diagnostics are in clinical studies with promising results. The company is targeting licensing deals with ~10 large diagnostic companies. Risks include no FDA approval yet, modest revenue, and capital intensity.